舒肝解郁胶囊对脑卒中后抑郁患者神经功能缺损的影响

目的探讨舒肝解郁胶囊对脑卒中后抑郁状态、神经功能缺损症状和日常生活能力的影响。方法将66例脑卒中后抑郁患者完全随机分为观察组和对照组，各33例。观察组在神经内科常规治疗的基础上，经1周清洗期后服用舒肝解郁胶囊，对照组进行神经内科常规治疗。2组患者治疗前及治疗第2、3、4周均进行汉密尔顿抑郁量表（HAMD）、美国国立卫生研究院卒中量表（NIHSS）和日常生活活动能力Barthel指数评分并加以比较。结果与治疗前比较，对照组经基础治疗3、4周后，HAMD评分未明显降低（P〉0．05），而观察组在口服舒肝解郁胶囊治疗3、4周后，其HAMD评分明显降低[分别为（10．1±2．1）、（7．8±2．0）分比（27．1±8．1）分]，差异有统计学意义（P〈0．01）；治疗3、4周，观察组和对照组NIHSS评分均明显降低[观察组：（7．3±1．7）、（3．9±1．7）分比（17．64-2．9）分；对照组：（9．4±2．0）、（6．2±1．9）分比（17．9±3．2）分，P〈0．05或P〈0．01]；对照组经基础治疗3周，其Barthel指数评分无明显升高（P〉0．05），而观察组治疗3周后，Barthel指数评分明显升高[（53±5）分比（27±6）分，P〈0．05]，治疗4周后，对照组和观察组的Barthel指数评分均明显升高[观察组：（74±6）分比（274-6）分；对照组：（54±7）分比（28±7）分，P〈0．05，P〈0．01]。与对照组比较，观察组治疗3、4周时，HAMD评分明显减少，差异有统计学意义（P〈0．05）；NIHSS评分较对照组减少，但差异无统计学意义（均P〉0．05）；治疗4周时，Barthel指数评分较对照组明显增高，差异有统计学意义（P〈0．05）。结论舒肝解郁胶囊是一种较理想的抗卒中抑郁药物，对改善脑卒中后抑郁及神经功能缺损症状和日常生活能力效果较明显。

Effects of Shuganjieyu capsule in post-stroke depression and nervous function defect

Objective To explore the effects of Shuganjieyu capsule on post-stroke depression, nervous function defect and activities of daily living. Methods All 66 patients with post-stroke depression were randomly divided into two groups： observation group （routine treatment combined with Shuganjieyu capsule） and control group （routine treatment only）. Hamilton rating scale for depression （HAMD）, national institutes of health stroke scale （NIHSS） and Barthel index score were used for the two groups before treatment and after treatment. Results Compared to before treatment, the score of HAMD did not decrease in control group（P 〉 0.05 ）, and decreased in observation group after treatment for 3 and 4 weeks [ （ 10. 1 ± 2.1 ）, （7.8 ± 2.0） scores vs （ 27.1 ±8.1 ） scores, P 〈 0.01 ] ; the score of NIHSS decreased obviously in observation group and control group after treatment for 3 and 4 weeks [ observation group ： （7.3 ±1.7 ）, （ 3.9 ± 1.7 ） scores vs （ 17.6 ±2.9 ） scores ; control group ： （9.4 ± 2. 0 ）, （ 6.2 ± 1.9） scores vs （ 17.9 ± 3.2） scores, P 〈 0.05 or P 〈 0.01 ] ; the score of Barthel index in observation group and control group increased significantly after treatment for 4 weeks [ observation group： （74 ± 6） scores vs （27 ± 6） scores ; control group ： （54 ± 7） scores vs （28 ± 7 ） scores, P 〈 0.05, P 〈 0.01 ]. Compared to the control group, HAMD scores in observation group decreased after treatment for three and four weeks, and there were significant difference between two groups （P 〈 0.05 ） ; the NIHSS in observation group were lower than those in control group, but there was no significant difference（P 〉 0.05） ; the score of Barthel index increased in observation group after treatment for four weeks, and the difference was significant （ P 〈 0.05 ）. Conclusion Shuganjieyu capsule is an ideal antidepressant which can improve post-stroke depression, the nervous function defect and activities of daily living.